| A randomized placebo-controlled crossover trial with phytoestrogens in treatment of menopause in breast cancer patients. | |
| | |
MedLine Citation:
|
PMID: 12798527 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: Phytoestrogens are popular in treatment of menopause, although scientific evidence is insufficient as to their efficacy. We studied the effects of daily use of isoflavonoids on climacteric symptoms and quality of life in patients with a history of breast cancer. METHODS: Sixty-two postmenopausal symptomatic women were randomized to use either phytoestrogen (tablets containing 114 mg of isoflavonoids) or a placebo for 3 months; the treatment regimens were reversed after a 2-month washout period. Fifty-six women completed the study. Menopausal symptoms were recorded on the Kupperman index and the visual analogue scale, and working capacity and mood changes were assessed via validated questionnaires. In addition, we followed the levels of phytoestrogens, follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol, and sex hormone-binding globulin. Liver enzymes and creatinine were also assessed at each visit. RESULTS: The phytoestrogen regimen raised the circulating levels of phytoestrogens (daidzein, genistein, equol) 19- to 106-fold. The Kupperman index was reduced by 4.2 +/- 9.6 (mean +/- standard deviation) (15.5%) during phytoestrogen use and similarly by 4.0 +/- 8.1 (14.7%) during placebo use (P nonsignificant). The quality of life parameters (working capacity, mood changes) were unaffected by phytoestrogen. In addition, the phytoestrogen regimen caused no changes in FSH, LH, estradiol, or sex hormone-binding globulin. Phytoestrogen treatment was well tolerated and caused no changes in liver enzymes, creatinine, body mass index, or blood pressure. Of the 56 women, 25 (44.6%) preferred the phytoestrogen regimen, 15 preferred the placebo (26.8%), and 16 (28.6%) reported no preference (nonsignificant). CONCLUSION: Pure isoflavonoids did not alleviate subjective menopausal symptoms in breast cancer patients. |
| | |
Authors:
|
Eini Nikander; Annamari Kilkkinen; Merja Metsä-Heikkilä; Herman Adlercreutz; Pirjo Pietinen; Aila Tiitinen; Olavi Ylikorkala |
Related Documents
:
|
7100847 - Occupational exposure to synthetic estrogens: some methodological problems. 12711997 - Hormone replacement therapy. current controversies. 11910667 - Polycystic ovary syndrome and implications for the menopause. 3779117 - Menopausal estrogen use and the risk of breast cancer. 12146847 - Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the us. 18375357 - Translation of recent advances and discoveries in molecular biology and immunology in t... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Obstetrics and gynecology Volume: 101 ISSN: 0029-7844 ISO Abbreviation: Obstet Gynecol Publication Date: 2003 Jun |
Date Detail:
|
Created Date: 2003-06-11 Completed Date: 2003-07-03 Revised Date: 2009-10-26 |
Medline Journal Info:
|
Nlm Unique ID: 0401101 Medline TA: Obstet Gynecol Country: United States |
Other Details:
|
Languages: eng Pagination: 1213-20 Citation Subset: AIM; IM |
Affiliation:
|
Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland. eini.nikander@pp.fimnet.fi |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Breast Neoplasms* Cross-Over Studies Double-Blind Method Estradiol / blood Estrogens, Non-Steroidal / blood, therapeutic use* Female Follicle Stimulating Hormone / blood Humans Isoflavones* Luteinizing Hormone / blood Phytoestrogens Plant Preparations Postmenopause / drug effects* Quality of Life Sex Hormone-Binding Globulin / analysis |
| Chemical | |
Reg. No./Substance:
|
0/Estrogens, Non-Steroidal; 0/Isoflavones; 0/Phytoestrogens; 0/Plant Preparations; 0/Sex Hormone-Binding Globulin; 50-28-2/Estradiol; 9002-67-9/Luteinizing Hormone; 9002-68-0/Follicle Stimulating Hormone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Physician cesarean delivery rates and risk-adjusted perinatal outcomes.
Next Document: Alcohol consumption and the risk of borderline and invasive ovarian cancer.